MedTrace Logo

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

NCT04045691 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2021-01-19

No results posted yet for this study

Summary

BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the SmPC (Summary of Product Characteristics).

Conditions

  • Melanoma Stage IV
  • Melanoma Stage III

Interventions

DRUG

Encorafenib

Observation of real-life treatment with encorafenib and binimetinib

DRUG

Binimetinib

Observation of real-life treatment with encorafenib and binimetinib

Sponsors & Collaborators

  • Pierre Fabre Pharma Austria

    collaborator UNKNOWN

  • Pierre Fabre Pharma AG

    collaborator INDUSTRY

  • Pierre Fabre Pharma GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-17
Primary Completion
2026-12-31
Completion
2027-09-30

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045691 on ClinicalTrials.gov